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STATEMENT OF INTEREST OF AMICUS CURIAE 
 Eileen M. Kane is Professor of Law at Penn State Dickinson School of Law. 
Professor Kane has a Ph.D. in molecular biology, and her legal scholarship has 
focused on the intersection of patent law and the life sciences, with particular 
attention to the patent eligibility of DNA. She is a registered attorney before the 
United States Patent and Trademark Office. Professor Kane has no financial 
interest in the above referenced case. This brief is submitted because of the 
continuing importance of striking a balance between the patent system and the 
public domain. Professor Kane submits this brief as amicus curiae pursuant to 
Federal Rule of Appellate Procedure 29(a). All parties have consented in writing to 
the filing of this brief. 
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SUMMARY OF THE ARGUMENT 
 This case is not complicated, when reduced to its fundamentals: is it possible 
to patent the genes and the correlations between genes and disease? Patent law has 
long accommodated a balance between an inviolable preserve of open knowledge 
and the gated zones of patented inventions. That balance is enforced through the 
patentable subject matter doctrine of 35 U.S.C. § 101. This challenge to the patent 
eligibility of the claimed genes and genetic correlations is important because of the 
long-established norms in patent law jurisprudence that laws of nature and natural 
products cannot be patented, and the possibility that illegitimate patent claims have 
preempted the use of knowledge tools that belong in the public domain.  
 There are two theories of patent ineligibility that can be applied to the gene. 
The gene is a DNA molecule with a specific patent ineligibility that results from its 
unique property as the repository of the genetic code. The patenting of genes 
preempts the use of the genetic code and thus violates the prohibition on patenting 
laws of nature. This theory of specific patent ineligibility does not implicate the 
patenting of other molecules in the life sciences. However, the gene is also 
generally ineligible for patenting in view of the product of nature doctrine, which 
requires the inventive alteration of any natural product before a patent can be 
granted. The isolated gene of the challenged patent claims is not altered from its 
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natural state, but simply reproduced outside the cell. It is a product of nature, and 
as such, cannot be patented. 
 The patenting of genetic correlations also violates the prohibition on 
patenting laws of nature, as the relationships between DNA and disease are 
prototypical laws of nature. As genetic medicine continues to develop, it is critical 
that the genotype-phenotype correlations which are essential to this field remain 
unpatented. More generally for the life sciences, it is essential to establish whether 
every observation of molecular performance can be converted into a patent claim. 
 Not everything can be patented. The Supreme Court has been quite clear that 
the laws of nature, natural phenomena, and abstract ideas are not patentable. The 
underlying rationale is that scientific advances depend on an available substrate of 
basic knowledge, and that, therefore, patenting the intellectual foundations of a 
field has an adverse effect on its progress. The exclusions from patentable subject 
matter are intended to keep foundational and uninvented knowledge available to all 
and outside the patent system. Neither genes nor genetic correlations are invented, 
yet the laws of nature embodied in these discoveries are preempted by the patent 
claims under challenge in this case. The district court properly identified the 
eligibility defects of the challenged patent claims, and its conclusion that these 
patent claims are invalid under 35 U.S.C. § 101 should be affirmed. 
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ARGUMENT 
I.  The Gene Has a Specific Patent Ineligibility  
 DNA is a unique molecule that functions as the chemical repository of 
inherited information which is written in the language of the genetic code. A gene 
is a natural embodiment of the genetic code, and the finite set of human genes 
comprise the human genome. The genetic code is a law of nature and as an 
essential component of the public domain in molecular biology. The patenting of 
genes preempts the genetic code, and is contrary to the Supreme Court’s 
prohibition on patenting laws of nature.  
 A.  The Genetic Code Is a Law of Nature 
 The discovery of the double helical structure of the DNA molecule 
suggested that hereditary information might be captured in a molecule with a novel 
structural design.  James D. Watson, DNA: The Secret of Life 53 (2004). The 
chemical analysis of DNA revealed that it was composed of a discrete set of 
nucleotides which were arranged sequentially. The molecular structure was then 
understood to convey an informational code which accounted for its ability to 
function as the hereditary material. Id. at 76. 
The genetic code, deciphered in 1966, explains the relationship between 
DNA and protein. The gene functions as a template according to the genetic code. 
“The genetic code is not the message itself but the ‘dictionary’ used by the cell to 
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translate from the four-letter language of nucleic acid to the 20-letter language of 
protein.” Frances Crick, The Genetic Code III, 215 Scientific American 55, 
October 1966. The genetic code describes a discrete set of fixed relationships 
between DNA and protein, mediated through RNA intermediates. It is a set of 
equivalences that dictate that a specific DNA sequence has a specific protein 
correlate. It is interchangeably used by disparate organisms across biology. The 
leading historian of the genetic code noted that its significance was apparent when 
the code’s universality among organisms was clear: “Universality was of course a 
highly prized feature. If true, then on the phenomenonological level it would 
elevate the genetic code to the pedestal of universal laws of nature, a privilege 
usually reserved for the Olympian reaches of physics.” Lily E. Kay, Who Wrote 
The Book Of Life?: A History Of The Genetic Code 276 (2000). 
 The genetic code is equivalent in status to the laws of physics previously 
recognized as laws of nature in the jurisprudence of patentable subject matter. “The 
laws of nature, physical phenomena, and abstract ideas have been held not 
patentable. Thus, a new mineral discovered in the earth or a new plant found in the 
wild is not patentable subject matter. Likewise, Einstein could not patent his 
celebrated law that E=mc2; nor could Newton have patented the law of gravity. 
Such discoveries are “manifestations of . . nature, free to all men and reserved 
exclusively to none.” Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). This 
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recitation of unpatentable scientific laws by the Supreme Court provides a firm 
basis for concluding that discoveries of scientific equivalences cannot be 
patentable subject matter; in fact, these are precisely the kinds of intellectual 
achievements that must be segregated from the patent system so that they can be 
used freely by all. The designation of the genetic code as a law of nature has 
implications for the patenting of its natural embodiments, which are the genes. 
B.  The Genes Are the Natural Embodiments of the Genetic Code and 
Are Not Invented  
 
 Genes are nature’s exemplars of the genetic code – as such, they embody 
this law of nature. The conversion of the genetic code into a human organism is 
accomplished by the particular set of formulas that are individually encapsulated as 
the genes. Extensive scientific efforts have been expended to locate and 
characterize the genes and to sequence the full human genome, finally culminating 
in the efforts of the Human Genome Project. International Human Genome 
Sequencing Consortium, Finishing the Euchromatic Sequence of the Human 
Genome, 431 Nature 931 (2004).  
 The gene, while formally described as a chemical compound, 
is functionally explained as a template. The dynamic gene operates by the laws of 
the genetic code. Activation of a gene initiates a sequence of metabolic events that 
unfold to accomplish the ultimate objective of generating a protein from a gene, a 
process generally known as gene expression. 
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 The use of the genetic code in genetic medicine is accomplished by research 
into the behavior of the genes, which dictate the structure and function of the 
human organism. While the science is novel and paradigm-shifting, it is only 
because it draws on the knowledge and use of the naturally occurring molecules, 
the genes, to arrive at a precise and individualized account of an individual’s 
genetic and biochemical identity. “[T]he ultimate consequences of the integration 
of genomics into medical research and medical practice are likely to be 
revolutionary.” Alan F. Guttmacher and Francis S. Collins, Realizing the Promise 
of Genomics in Biomedical Research, 294 Journal of the American Medical 
Association 1399 (2005). 
 The use of the genes is critical because these molecules carry the natural 
templates of the human organism. Despite the technical work that underlies the 
identification and sequencing of the natural genes, there can be no dispute that 
such efforts do no more than reveal a natural blueprint. “The genome sequence is a 
discovery, not an invention.” John Sulston & Georgina Ferry, The Common 
Thread: A Story Of Science, Politics, Ethics, And The Human Genome 266 (2002). 
 Accordingly, because the genes function as templates through their 
embodiment of the genetic code, the eligibility analysis of these molecules 
necessarily implicates the effect of patenting on the availability of this underlying 
law of nature. More precisely for patent law, this question is generally framed as 
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investigating whether a law of nature is preempted by the grant of a patent claim. 
“[C]claims which directly or indirectly preempt natural laws or phenomena are 
proscribed.” In re Bergy, 596 F.2d 952, 988 (C.C.P.A. 1979). 
C.  The Patenting of Genes Preempts the Genetic Code, and Is 
Invalid According to the Supreme Court’s Prohibition Against 
Patenting Laws of Nature 
 
 When a law of nature or an abstract idea, which itself is unpatentable, has 
only certain embodiments, the Supreme Court has been alert to possible 
preemption of the underlying idea through patenting: 
  “It is conceded that one may not patent an idea. But in practical effect 
that would be the result if the formula for converting BCD numerals 
to pure binary numerals were patented in this case. The mathematical 
formula involved here has no substantial practical application except 
in connection with a digital computer, which means that if the 
judgment below is affirmed, the patent would wholly pre-empt the 
mathematical formula and in practical effect would be a patent on the 
algorithm itself.”   
 
Gottschalk v. Benson, 409 U.S. 63, 71-72 (1972). By analogy, the only 
embodiments of the genetic code are the genes, and while the genetic code itself 
cannot be patented, the patenting of genes effectively preempts the use of the 
genetic code. The resolution of eligibility for the class of genes will be determined 
by a proper patentable subject matter analysis of one challenged and representative 
gene patent claim, an opportunity presented by this litigation. Each gene patent has 
preemptive effect because it withdraws the use of one of nature’s genetic formulas. 
That is exactly what has happened with the patent claims on the BRCA1 and 
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BRCA2 genes. Although the patent claims are formally directed to “isolated 
DNA,” the actual DNA sequence is the sequence of the native gene. The merger 
doctrine from copyright law supplies a relevant theoretical analysis: if an idea has a 
set of finite expressions, then property rights in the expressions are tantamount to 
ownership of the underlying idea; effectively, the idea and the expressions merge. 
Baker v. Selden, 101 U.S. 99 (1879). By analogy, the merger doctrine framework is 
helpful in understanding that the genes are the natural set of expressions of the 
genetic code, and their patenting effectively preempts the genetic code itself. 
Eileen M. Kane, Splitting the Gene: DNA Patents and the Genetic Code, 71 
Tennessee Law Review 707, 753 (2004). 
 It is well established in patent jurisprudence that “natural phenomena, 
abstract ideas, and laws of nature” may not be patented. Diamond v. Diehr, 450 U. 
S. 175, 185 (1981). Just this year, the Supreme Court reaffirmed the continuing 
vitality of these exclusions: “The concepts covered by these exceptions are “part of 
the storehouse of knowledge of all men …free to all men and reserved exclusively 
to none.” Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010), quoting Funk Brothers 
Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948). These categories of 
unpatentable subject matter have been carefully identified and maintained by the 
Supreme Court. In fact, the Court has been clear about its rationale for these 
exclusions: “Phenomena of nature, though just discovered, mental processes, and 
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abstract intellectual concepts are not patentable, as they are the basic tools of 
scientific and technological work.” Gottschalk v. Benson, 409 U.S. 63, 67 (1972). 
 The challenged composition of matter claims capture the naturally occurring 
wild-type genes or naturally occurring mutated genes that correspond to the human 
BRCA1 and BRCA2 gene sequences, although described in the claim language of 
“isolated DNA” (Claims 1, 2, and 7 of U.S. Patent 5,747,282; Claims 1, 6, and 7 of 
U.S. Patent 5,837,492 and Claim 1 of U.S. Patent 5,693,473), and are invalid. 
Patent claims that comprise fragments of the BRCA1 gene can also operate to 
cover the use of the full-length gene (Claims 5 and 6 of U.S. Patent 5,747,282), 
and such claims are invalid as they encompass ineligible subject matter.  All of 
these nucleotide sequences are identical to the naturally occurring nucleotide 
sequences that perform the work of the native BRCA1 and BRCA2 genes. They 
are natural and uninvented expressions of the genetic code, and have preemptive 
effect. 
 The genetic code, which is an unpatentable law of nature, does not 
effectively reside in the public domain if private rights are held in DNA gene 
sequences, so that the use of the biologically relevant expressions of the genetic 
code - the genes - cannot occur without permission from a patent holder. The 
patenting of genes, therefore, results in preemption of the genetic code, an outcome 
that conflicts with the Supreme Court’s dictate that the laws of nature should 
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remain in the public domain, free for all to use.  Accordingly, the composition of 
matter claims (Claims 1, 2, 5, 6 and 7 of U.S. Patent 5,747,282; Claims 1, 6, and 7 
of U.S. Patent 5,837,492 and Claim 1 of U.S. Patent 5,693,473) are invalid for lack 
of patentable subject matter under 35 U.S.C. § 101. 
D.  The Specific Patent Ineligibility of a Gene Does Not Implicate the 
Patenting of Other Biomolecules 
 
 DNA, as the chemical repository of genetic information, has a complex 
identity.  The universal language of inheritance – the genetic code – can be 
embodied as a sequence of nucleotide chemicals.  The gene is both the static 
chemical compound and the dynamic template executed through the genetic code. 
Not surprisingly, the eligibility analysis of this molecule is complicated by its 
multidimensional character, and the above analysis presents a specific theory of 
patent ineligibility that is DNA-centric. What is at stake here is whether patents 
can be granted on the discovered finite set of genetic formulas that are the genes, 
and this question is quite singular for the field of patent law. 
 Concern has been expressed that a decision regarding the eligibility of a 
patent claim on a gene will call into question the patenting of other biomolecules, 
and chill innovation in biotechnology.  Association for Molecular Pathology v. 
U.S. Patent & Trademark Office, 702 F. Supp.2d 181, 211 (S.D.N.Y. 2010). That 
is not accurate.  For the reasons outlined here, the gene, claimed as an isolated 
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DNA molecule, has a set of unique attributes that demand a more complicated 
eligibility analysis than would be required for other molecules. It is possible to 
reach a decision regarding the DNA eligibility issue using the foregoing theory of 
specific patent ineligibility to arrive at a conclusion that does not affect the 
patenting of other biological molecules.   
 Moreover, the central issue presented in this case is whether the most basic 
discoveries of genetic sciences – finding the genes and identifying their functions – 
are candidates for patenting. A decision from this court that these essential 
scientific tools should remain in the public domain does not deprive the 
biotechnology industry of other patenting opportunities. In fact, maintaining the 
essential knowledge tools in the public domain is the predicate for the value-added 
creativity that converts discovery into invention. The patent system is charged with 
encouraging inventive activity, not rewarding discoveries.  
II.  The Gene Has a General Patent Ineligibility As a Product of Nature 
 The foregoing characterization of DNA and its identity as a chemically 
incorporated template is also relevant to a separate theory of ineligibility, which is 
based on the exclusions of products of nature from patenting. The Supreme Court 
has instructed that the removal of a natural product from its environment – a 
product of nature – does not qualify as an inventive act which authorizes the grant 
of patent on the product. When considering whether a genetically engineered 
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bacterium was an invented product, the Court noted that the patentable subject 
matter inquiry must distinguish “between products of nature, whether living or not, 
and human-made inventions.” Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980). 
However, the Court has recognized that inventive status may be conferred when 
the natural product has “markedly different characteristics” than the natural 
product. Id. at 310. The Court recognized that patent eligibility could be satisfied 
by a “product of human ingenuity” “having a distinctive name, character [and] 
use.” Id. at 309-10. 
 The comparison of the “isolated DNA” in the above-referenced composition 
of matter claims on wild-type and mutant genes to the naturally occurring genes 
has two separate inquiries. These are the questions of structure and function. Is the 
isolated DNA structurally identical to the native gene? Does the isolated DNA 
function in the same manner as the native gene?  
 The purified gene is often claimed as an isolated complementary DNA 
(cDNA) – the abbreviated, message-bearing form of the gene, a result of laboratory 
manipulation, reflecting divergence from the physical genomic form. Bruce 
Alberts et al., Molecular Biology of the Cell 503, 4th edition (2002). However, all 
of that structural investment is done to preserve the natural informational content 
of the gene – the maintenance of its functional identity. The goal of recovering the 
natural gene sequence as an isolated DNA is to preserve the informational content 
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of the molecule so that it is identical to the native gene. That identity is essential 
for using an isolated gene in medically-related applications, such as genetic testing 
or gene therapy. Any deviation from the natural DNA sequence would compromise 
the use of the isolated DNA as the functional equivalent of the gene in the cell. The 
mimicry of the native gene undermines any assertion that an inventive alteration 
has occurred. Accordingly, the composition of matter claims (Claims 1, 2, 5, 6 and 
7 of U.S. Patent 5,747,282, Claims 1, 6, and 7 of U.S. Patent 5,837,492 and Claim 
1 of U.S. Patent 5,693,473) are invalid for lack of patentable subject matter under 
35 U.S.C. § 101. 
 Resolution of patent eligibility for a gene under the product of nature 
doctrine does implicate the patenting of other biomolecules, but only in the sense 
that the doctrine can be used to assess other patenting efforts in the life sciences. 
However, the product of nature doctrine has a long pedigree in patent law, 
completely separate from any analysis of DNA, and a determination that genes are 
ineligible for patenting does not preclude the patent eligibility of the truly 
inventive alterations of natural products. 
III.  The Relationship Between Genotype and Phenotype Is a Law of Nature 
and Cannot Be Patented as a Method Claim 
 
 There are several insights from genetic science that account for the paradigm 
shift that genetic science has brought to medicine. The first is that the genetic code 
is captured in a set of DNA molecules, which are the genes. The genome is the 
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actual full set. There is some DNA sequence variation (mutations) among human 
beings, which account for the biological diversity of the human species. The next 
insight is that the medical status of an individual can depend on the actual DNA 
sequences that are found in her genome. This observation is described as the 
functional relationship between genotype (the DNA sequence) and phenotype (the 
actual biological consequence of that sequence). How does DNA sequence 
variation account for medical individuality? It is because an altered DNA molecule 
will encode an altered protein, and that mutated protein will behave erratically or 
not at all, with a disruption to normal cellular function, resulting is disease. The 
above description captures the causation sequence between DNA and disease, 
where genotype dictates phenotype. Bruce Alberts et al., Molecular Biology of the 
Cell 525, 4th edition (2002). 
 The genotype-phenotype correlation is, therefore, a naturally occurring 
relationship. It is certainly a natural phenomenon or a law of nature, as it can only 
be discovered, not invented. Genetic medicine is the use of these natural 
correlations to offer a personalized medical profile to a patient, and to devise 
treatments that are informed by the knowledge of any underlying genetic 
aberration. 
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 It is not possible to patent the genotype-phenotype correlation, as it is solely 
a law of nature. In fact, these correlations are so natural - and potentially 
problematic - that genetic medicine is devoted to the investigation of these 
inherited genetic dictates through the use of genetic testing. For example, a genetic 
test can be used to determine the DNA sequences of the BRCA1 and/or BRCA2 
genes in a patient, in order to investigate whether the individual carries the DNA 
mutations in the genes that are associated with a higher risk of developing early 
onset breast or ovarian cancer. That is a prototypical example of using the 
genotype-phenotype relationship in medical care. The study of gene mutations 
which confer clinical risk allows disease to be explained through precise molecular 
mechanisms. Piri L. Welsch et al., BRCA1 and BRCA2 and the Genetics of Breast 
and Ovarian Cancer, 10 Human Molecular Genetics 705 (2001). As a result, a 
patient can be offered a more personalized assessment of risk, diagnosis and/or 
prognosis, and therapeutic regimens can be individually optimized. 
 What is at stake in this litigation is whether the basic relationship between 
the genotype (the DNA sequence) and the phenotype (cancer risk) can be patented 
in the form of the challenged method patent claims which effectively describe the 
act of comparing a patient’s BRCA1 or BRCA2 DNA sequence to the normal 
DNA sequences for these genes in order to identify any mutations and identify 
cancer risk.  
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 The challenged patent method claims can be deconstructed. A patent claim 
written as a method of “detecting a germline alteration” is simply a patent method 
claim that seeks to patent any use of the medically significant mutations in the 
BRCA1 gene (Claim 1 of U.S. Patent 5,709,999). A patent claim which describes a 
method of “comparing” DNA sequences is simply a patent method claim that seeks 
to monopolize the foundational observation that knowledge of the BRCA1 or 
BRCA2 genotype of a patient will be relevant to assessment of her risk for 
developing breast or ovarian cancer (Claim 1 of U.S. Patent 5,753,441, Claims 1 
and 2 of U.S. Patent 6,033,857). A patent claim which describes a method of 
“screening” for a “somatic alteration” in a tumor cell is simply a patent method 
claim that will control the use of the knowledge that a naturally-arising mutation in 
the BRCA1 gene in a tumor sample from a patient may have clinical impact 
(Claim 1 of U.S. Patent 5,710,001). All of these patent claims, upon inspection, 
can be reduced to the same structure: the claim confers a monopoly on the use of 
the natural relationship between a patient’s BRCA1 or BRCA2 genotype and her 
clinical profile. The conclusion is clear: through the format of a patent method 
claim, any use of a genotype-phenotype correlation, which is an unpatentable law 
of nature, is controlled by the patent holder. This outcome does not comport with 
well-established principles of eligibility in patent law that distinguish valid from 
invalid patent method claims. “The rule that the discovery of a law of nature 
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cannot be patented rests, not on the notion that natural phenomena are not 
processes, but rather on the more fundamental understanding that they are not the 
kind of ‘discoveries’ that the statute was enacted to protect.” Parker v. Flook, 437 
U.S. 584, 593 (1978). 
The significance of determining whether scientific correlations are eligible 
for patenting cannot be overstated. Beyond the identification of the molecules that 
perform biochemical tasks, modern biological research focuses on determining 
dynamic intermolecular relationships and biochemical causation. The potential 
method claims in biochemical or genetic testing are quite heterogeneous, where a 
patent claim may cover, for example, quantitative relationships between molecules, 
the mechanism of pharmaceutical metabolism, or the cause and effect relationship 
between genotype and phenotype. While the universe of biological molecules may 
be finite, the set of relationships and interactions that define human metabolism are 
likely to be vast. It is essential for the Court to establish whether every observation 
of molecular performance can be converted into a patent claim. 
 At the time of the district court decision, the analytic framework for 
assessing the eligibility of method claims was the machine or transformation test 
that arose from the business method patent disputes; the Supreme Court later 
decided that this test would not be the sole determinant of method claim eligibility. 
Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010). Thus, the method claims in the 
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instant case have not been analyzed for their possible violation of the prohibition 
against the patenting of laws of nature or natural phenomena. The Court now has 
the opportunity to assess the method claims to genetic correlations in a more 
appropriate eligibility framework. It should conclude that the method patent claims 
which effectively capture genotype-phenotype correlations (Claim 1 of U.S. Patent 
5,709,999, Claim 1 of U.S. Patent 5,753,441, Claim 1 of U.S. Patent 5,710,001, 
and Claims 1 and 2 of U.S. Patent 6,033,857) are invalid for lack of patentable 
subject matter under 35 U.S.C. § 101.1 
IV.  Access to the Basic Tools of Genetic Science is Critical for the Patent 
System and the Scientific Enterprise 
 
 Not everything can be patented. The Supreme Court has been quite clear that 
“laws of nature, natural phenomena, and abstract ideas” are not patentable, 
although the interpretation of this maxim has been difficult. Yet, the underlying 
rationale is that scientific advances depend on an available substrate of basic 
knowledge, and that, therefore, patenting the intellectual foundations of a field has 
an adverse effect on its progress. The patentable subject matter doctrine in patent 
law - patent eligibility - performs this necessary gatekeeping function. The 
appropriate application of patent eligibility criteria is necessary in order that the 
patent system remain bounded by limitations which preserve the substrate of 
                                                 
1 This brief takes no position on the patent eligibility of Claim 20 of U.S. Patent 
5,747,282, which is not directed to a gene or genetic correlation. 
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common knowledge tools that can be freely drawn upon for intellectual creativity 
and scientific progress. This is particularly important for emerging fields of 
knowledge, as researchers uncover the essential knowledge that defines and 
coheres the field, and modern genetic science, which offers a new paradigm for 
understanding and treating disease, is such a field. Genetic testing can be used to 
identify disease susceptibility, to establish diagnostic status, and to design 
personalized therapeutic regimens in medical care. Any illegitimate patenting not 
only limits scientific research; it also impacts patient care. 
 It is not possible to invent around patented genes. There are no substitutes. If 
the patenting of genes and genetic correlations has occurred in violation of the 
exclusions from patentable subject matter, the patent owner is able to set the 
intellectual agenda for an entire clinical field, and decisions regarding access and 
comparative research can be dictated by commercial objectives. This outcome 
highlights the importance of the patent eligibility questions posed by this litigation. 
 Restrictive management of gene patents with critical diagnostic significance 
limits peer assessment, and lessens the available testing options for patients. If the 
sole commercial provider of a particular genetic test does not offer a 
comprehensive genetic analysis, the test will not provide the most accurate 
assessment of genetic status, and compensatory genetic testing to correct 
deficiencies may be prohibited by the patent holder. The actual genetic testing field 
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will then be defined by a divergence between the theoretically optimal and the 
commercially available. An artificially constrained genetic testing climate can 
result in patients receiving incomplete test results that cannot be relied on for 
medical decision making. Association for Molecular Pathology v. U.S. Patent & 
Trademark Office, 702 F. Supp.2d 181, 206 (S.D.N.Y. 2010). The limitations on 
commercial genetic testing for the BRCA1 and BRCA2 genes to determine the risk 
of hereditary breast and ovarian cancer which are imposed by Myriad Genetics 
also prevent women from seeking second opinions or confirmatory analysis of 
laboratory results. Id. at 207. Where exclusive control of the relevant patent 
portfolio for a particular disease field is used to frustrate a competitive genetic 
testing environment, the de facto clinical testing standards are set by a patent 
holder, rather than the scientific community. The clinical standard then becomes a 
function of the marketplace, rather than the laboratory. Eileen M. Kane, Patent-
Mediated Standards in Genetic Testing, 2008 Utah Law Review 835, 849. 
 The other doctrinal requirements for patentability (utility under 35 U.S.C. § 
101, novelty under 35 U.S.C. § 102, nonobviousness under 35 U.S.C. § 103, or the 
disclosure doctrines of 35 U.S.C. § 112) can influence the scope of patent claims 
and the relative availability of patent rights, but these doctrines are not charged 
with the categorical determinations that necessarily result from judgments 
regarding patentable subject matter. It is precisely these categorical consequences 
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that turn decisions of patent eligibility into determinants of the intellectual climate 
of a field, as the contours of free and common knowledge are shaped by the courts 
when they properly apply 35 U.S.C. § 101. 
 It has been argued that gene patents are necessary to incentivize genetic 
research and the development of genetic tests. Association for Molecular 
Pathology v. U.S. Patent & Trademark Office, 702 F. Supp.2d 181, 211 (S.D.N.Y. 
2010). The Secretary’s Advisory Committee on Genetics, Health and Society 
(SACGHS), undertook a recent and comprehensive analysis on the need for and 
impact of patents affecting genetic testing. “[T]his information suggests that 
scientists are motivated to conduct genetic research by reasons other than patents, 
suggesting that discoveries will be sought regardless of the availability of 
intellectual property rights.” The Secretary’s Advisory Committee on Genetics, 
Health and Society, Gene Patents and Licensing Practices and Their Impact on 
Patient Access to Genetic Tests 23 (April 2010). A further conclusion was reached 
for the relationship between patents and commercial genetic tests: “[P]atent-
derived exclusive rights are neither necessary nor sufficient conditions for the 
development of genetic test kits and laboratory-developed tests. In the area of 
laboratory-developed tests particularly, where development costs are not 
substantial, patents were not necessary for the development of several genetic 
tests.” Id. at 35. The genetic tests offered by Myriad Genetics fall into the latter 
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category of laboratory-developed tests. It is not possible to resolve the conflict 
between the empirical research demonstrating that gene patents do not account for 
much of the progress in genetic science and the assertions that the disqualification 
of gene patents will have devastating consequences on biomedical innovation. 
However, it is possible to state that any ineligible patent claims in force have the 
effect of artificially constraining the set of knowledge tools in the public domain, a 
consequence that certainly reduces innovation by imposition of a chilling effect. It 
is important to acknowledge that the existence of a vibrant public domain is a key 
prerequisite for scientific inquiry and intellectual progress. 
 Technological and intellectual imperatives create the possibility of patenting 
novel forms of subject matter that test the patent system. The controversies over 
patentable subject matter, while centered in difficult legal questions regarding line-
drawing, can be traced to instances where patenting alters the expectations of what 
comprises the public domain, including such knowledge categories such as genetic 
laws and business practices. Public confusion that attends to the patenting of genes 
or business methods may reflect an unarticulated, background view of the public 
domain, only made visible when its boundaries appear to collapse. This dimension 
of the patent system may be its most public face, as it presents some binary choices 
regarding what is allowed or what is not. However, in the sense that the patent 
system is viewed as a mechanism for encouraging the development and 
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dissemination of new knowledge, judicial attention to the dividing line between 
public and private in patent law could not be a more important task. “A patent by 
its very nature is affected with a public interest. As recognized by the Constitution, 
it is a special privilege designed to serve the public purpose of promoting the 
‘Progress of Science and useful Arts.’”Precision Instrument Mfg. Co. v. Auto. 
Maint. Mach. Co., 324 U.S. 806, 816 (1944) (quoting U.S. CONST. art I, § 8, cl. 
8). Although bioethical and human rights objections have been raised to the 
patenting of genes and genetic correlations, it is clear that patent law jurisprudence 
itself provides the basis for declaring that the discoveries of genetic science cannot 
be patented, using the theories outlined in this brief.  
 Resolution of the eligibility controversies in genetic patenting is important 
for genetic medicine and also has larger theoretical implications. The life sciences 
await a definitive and modern interpretation of the product of nature doctrine and 
its scope, and a contemporaneous analysis of whether and how correlations in the 
life sciences are regarded as natural phenomena or laws of nature. The Court has 
an opportunity to update the set of “basic tools” for genetic science, and to settle 
these eligibility controversies for the benefit of scientists, medical practitioners, 
and patients who wish to use isolated genes and genetic correlations in research 
and medical care.  
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 The patenting of applied research and true invention can coexist alongside 
the preserve of open and available knowledge, and both will contribute to future 
developments in genetic science. The inventive precision enforced through the 
proper application of 35 U.S.C. § 101 will allow creative applications of 
fundamental knowledge to emerge and legitimately solicit legal protection, while 
the intellectual substrates for genetic science remain unowned. That is the optimal 
balance for an effective patent system. 
CONCLUSION 
 For the reasons stated, the judgment of the District Court that the patent 
claims on genes and genetic correlations are invalid for lack of patentable subject 
matter under 35 U.S.C. § 101 should be affirmed. 
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